Recurrent Seizures and Serotonin Syndrome Following 2C-I" Ingestion"

被引：37

作者：

Bosak A. ^{[1
]}

LoVecchio F. ^{[1
]}

Levine M. ^{[1
,2
]}

机构：

[1] Department of Medical Toxicology, Banner Good Samaritan Medical Center, Phoenix, AZ

[2] Department of Emergency Medicine, Section of Medical Toxicology, University of Southern California, Los Angeles, CA

来源：

Journal of Medical Toxicology | 2013年 / 9卷 / 2期

关键词：

2C-I; 2CI; Phenethylamine; Rave; Seizure; Serotonin syndrome;

D O I：

10.1007/s13181-013-0287-x

中图分类号：

学科分类号：

摘要：

The phenethylamines, including 2, 5 dimethoxy-4-iodophenethylamine, commonly referred to as 2C-I, have recently emerged as a new class of designer drugs. Cases of toxicity from these drugs are not well described in the literature. This case report describes a 19 year-old male who insufflated 2C-I. Following the ingestion, the patient developed recurrent seizures, and was taken to the emergency department, where he was noted to be hyperadrenergic and had recurrent seizures. The patient was diagnosed with serotonin syndrome and experienced prolonged respiratory failure, although he ultimately made a full recovery. Comprehensive drug testing revealed the presence of 2C-I. The pharmacologic properties of 2C-I are also discussed. © 2013 American College of Medical Toxicology.

引用

页码：196 / 198

页数：2

共 13 条

[1]

Haroz R., Greenberg M.I., Emerging drugs of abuse, Med Clin N Am, 89, pp. 1259-1276, (2005)

[2]

Andreasen M.F., Telving R., Birkler R.I., Et al., A fatal poisoning involving Bromo-Dragonfly, Forensic Sci Int, 183, pp. 91-96, (2009)

[3]

Theobald D.S., Putz M., Schneider E., Et al., New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic-mass spectrometric and capillary electrophoretic/mass spectrometric techniques, J Mass Spectrom, 41, pp. 872-886, (2006)

[4]

Johnson M.P., Mathis C.A., Shuligin A.T., Et al., [125I]-2-(2, 5-Dimethoxy-4-iodophenyl)aminoethane ([125]-2C-I) as a label for the 5HT2 receptor in rat frontal cortex, Pharmacol Biochem Behav, 35, pp. 211-217, (1990)

[5]

Castillo A.C., Villalobos C., Moya P.R., Et al., Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5HT<sub>2A</sub> and 5HT<sub>2C</sub> receptors, Br J Pharmacol, 136, pp. 510-519, (2002)

[6]

Nagai F., Nonaka R., Satoh Hisashi Kamimura K., The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain, Eur J Pharmacol, 559, pp. 132-137, (2007)

[7]

Maurer H.H., Chemistry, pharmacology, and metabolism of emerging drugs of abuse, Ther Drug Monit, 32, pp. 544-549, (2010)

[8]

Theobald D.S., Maurer H.H., Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2c-series), Biochem Pharmacol, 73, pp. 287-297, (2007)

[9]

Microgram Bulletin, 38, pp. 48-49, (2004)

[10]

DeBoer D., Gijzeles M.J., Bosman I.J., Et al., More data about the new psychoactive drug 2C-B, J Anal Toxicol, 23, pp. 227-228, (1999)

← 1 2 →